Authors
Latest:
How HEOR Can Claim the SpotlightIf HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.
Latest:
Pragmatic Therapy: Balancing Innovation, Cost, and Careis spectacular science enough to guarantee success for new medicines?
Latest:
Multidisciplinary Care Teams: Challenge or Opportunity?Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.
Latest:
QIDP: An Insufficient Policy?The GAIN Act creates a process for the Qualified Infectious Disease Product (QIDP) designation, which provides a range of incentives for developing antimicrobial therapies for combating resistant organisms. But while the program has been successful in driving innovation, commercial viability remains a question.
Latest:
Taking Command of Strategy ExecutionMark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.
Latest:
The Power of MSL AuthenticityPaul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.
Latest:
US Healthcare Could Be the Booster Shot That “Healthy China” NeedsThe Chinese government's “Healthy China” plan presents an unprecedented opportunity for the US healthcare industry and its investors, writes Steven Shill.
Latest:
Lessons Learned from the Multichannel ShakeoutInnovation by itself won't solve the complex multichannel challenges pharmas face.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Dermatology Biologics: Overcoming Challenges to Fulfill Therapeutic PotentialDarcee Strube offers an overview of the key issues and progress made in dermatology biologics.
Latest:
America’s Opioid Crisis: Potential Increased Regulation of MarketingWith over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit, or at least impose greater control over, marketing as a strategy to reduce the prescription, and more specifically, the improper and/or over-prescription of opioids.
Latest:
America’s Opioid Crisis: Potential Increased Regulation of MarketingWith over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit, or at least impose greater control over, marketing as a strategy to reduce the prescription, and more specifically, the improper and/or over-prescription of opioids.
Latest:
Drug Delivery’s Role in Improving Rural OutcomesIn the search for effective and efficient ways to bridge the urban/rural divide, technological advances are offering more and more solutions.
Latest:
Best Practices For Building Scalable R&D Data PlatformsThis article discusses the best practices for transforming legacy approaches of managing data into modern ones capable of achieving the ambitious visions of pharmaceutical companies.
Latest:
Olivier Laureau, Servier: Free to Grow, InnovateFrench independent pharma Servier Group, led by president Olivier Laureau, is uniquely positioned to capitalize on new opportunities for expansion and stay true to its R&D and patient-focused mission.
Latest:
From Lab to Life: Improving Patient Lives through Community-based Healthcare and Decentralized Clinical TrialsIn Episode Three of the Syneos Health Dedicated Dialogue podcast series, we uncover how the proliferation of new digital health technologies, telemedicine and mobile nursing services are helping fuel novel clinical trials. These range from community-based studies, which are administered through PCPs, local health centers and outpatient facilities in lieu of academic research centers, to hybrid and fully virtual trials designed around patients in their homes, with or without a synthetic control arm replacing patients on placebos. Additionally, we share new insights about how trial sponsors discovering new ways to engage participants, enhance data capture and devise pathways to put patients at the center of clinical trials across the biopharmaceutical product development continuum.
Latest:
Compliance Information at a ClickTracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.
Latest:
Master Data Management 2.0Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.
Latest:
The Top Barriers to Patient PersistenceAnd ways pharma can help overcome these hurdles-and boost compliance rates across the full durations of treatment
Latest:
AI in the Medical Domain: Not a Quick FixDanish Gupta discuss the current strengths and weaknesses of artificial intelligence applications in life sciences.
